vs
Apellis Pharmaceuticals, Inc.（APLS）与PROSPERITY BANCSHARES INC（PB）财务数据对比。点击上方公司名可切换其他公司
PROSPERITY BANCSHARES INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.8倍（$367.6M vs $199.9M），PROSPERITY BANCSHARES INC净利率更高（31.6% vs -29.5%，领先61.1%），过去两年PROSPERITY BANCSHARES INC的营收复合增速更高（19.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Prosperity Bancshares Inc.是总部位于美国得克萨斯州休斯顿的银行控股公司，业务覆盖得克萨斯州及俄克拉荷马州中部。截至2019年12月31日，公司共运营285家分支机构，广泛分布在休斯顿、达拉斯-沃斯堡都会区及得州南部、东部、中部、西部等区域。
APLS vs PB — 直观对比
营收规模更大
PB
是对方的1.8倍
$199.9M
净利率更高
PB
高出61.1%
-29.5%
两年增速更快
PB
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $367.6M |
| 净利润 | $-59.0M | $116.3M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 31.6% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | -10.7% |
| 每股收益（稀释后） | $-0.40 | $1.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPB
| Q1 26 | — | $367.6M | ||
| Q4 25 | $199.9M | $275.0M | ||
| Q3 25 | $458.6M | $273.4M | ||
| Q2 25 | $178.5M | $267.7M | ||
| Q1 25 | $166.8M | $265.4M | ||
| Q4 24 | $212.5M | $267.8M | ||
| Q3 24 | $196.8M | $261.7M | ||
| Q2 24 | $199.7M | $258.8M |
净利润APLSPB
| Q1 26 | — | $116.3M | ||
| Q4 25 | $-59.0M | $139.9M | ||
| Q3 25 | $215.7M | $137.6M | ||
| Q2 25 | $-42.2M | $135.2M | ||
| Q1 25 | $-92.2M | $130.2M | ||
| Q4 24 | $-36.4M | $130.1M | ||
| Q3 24 | $-57.4M | $127.3M | ||
| Q2 24 | $-37.7M | $111.6M |
营业利润率APLSPB
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 65.1% | ||
| Q3 25 | 48.7% | 64.4% | ||
| Q2 25 | -18.6% | 64.3% | ||
| Q1 25 | -50.0% | 62.7% | ||
| Q4 24 | -12.3% | 62.0% | ||
| Q3 24 | -24.0% | 62.1% | ||
| Q2 24 | -14.7% | 55.2% |
净利率APLSPB
| Q1 26 | — | 31.6% | ||
| Q4 25 | -29.5% | 50.9% | ||
| Q3 25 | 47.0% | 50.3% | ||
| Q2 25 | -23.6% | 50.5% | ||
| Q1 25 | -55.3% | 49.1% | ||
| Q4 24 | -17.1% | 48.6% | ||
| Q3 24 | -29.2% | 48.6% | ||
| Q2 24 | -18.9% | 43.1% |
每股收益（稀释后）APLSPB
| Q1 26 | — | $1.16 | ||
| Q4 25 | $-0.40 | $1.48 | ||
| Q3 25 | $1.67 | $1.45 | ||
| Q2 25 | $-0.33 | $1.42 | ||
| Q1 25 | $-0.74 | $1.37 | ||
| Q4 24 | $-0.30 | $1.36 | ||
| Q3 24 | $-0.46 | $1.34 | ||
| Q2 24 | $-0.30 | $1.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $8.2B |
| 总资产 | $1.1B | $43.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSPB
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
股东权益APLSPB
| Q1 26 | — | $8.2B | ||
| Q4 25 | $370.1M | $7.6B | ||
| Q3 25 | $401.2M | $7.7B | ||
| Q2 25 | $156.3M | $7.6B | ||
| Q1 25 | $164.2M | $7.5B | ||
| Q4 24 | $228.5M | $7.4B | ||
| Q3 24 | $237.1M | $7.4B | ||
| Q2 24 | $264.3M | $7.3B |
总资产APLSPB
| Q1 26 | — | $43.6B | ||
| Q4 25 | $1.1B | $38.5B | ||
| Q3 25 | $1.1B | $38.3B | ||
| Q2 25 | $821.4M | $38.4B | ||
| Q1 25 | $807.3M | $38.8B | ||
| Q4 24 | $885.1M | $39.6B | ||
| Q3 24 | $901.9M | $40.1B | ||
| Q2 24 | $904.5M | $39.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSPB
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $78.3M | ||
| Q3 25 | $108.5M | $194.8M | ||
| Q2 25 | $4.4M | $98.2M | ||
| Q1 25 | $-53.4M | $178.2M | ||
| Q4 24 | $19.4M | $-205.8M | ||
| Q3 24 | $34.1M | $274.6M | ||
| Q2 24 | $-8.3M | $216.5M |
自由现金流APLSPB
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $68.5M | ||
| Q3 25 | $108.3M | $185.7M | ||
| Q2 25 | $4.4M | $91.8M | ||
| Q1 25 | $-53.4M | $171.1M | ||
| Q4 24 | $19.3M | $-210.7M | ||
| Q3 24 | — | $270.2M | ||
| Q2 24 | $-8.4M | $211.8M |
自由现金流率APLSPB
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 24.9% | ||
| Q3 25 | 23.6% | 67.9% | ||
| Q2 25 | 2.5% | 34.3% | ||
| Q1 25 | -32.0% | 64.5% | ||
| Q4 24 | 9.1% | -78.7% | ||
| Q3 24 | — | 103.3% | ||
| Q2 24 | -4.2% | 81.8% |
资本支出强度APLSPB
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 3.6% | ||
| Q3 25 | 0.0% | 3.3% | ||
| Q2 25 | 0.0% | 2.4% | ||
| Q1 25 | 0.0% | 2.7% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 1.8% |
现金转化率APLSPB
| Q1 26 | — | — | ||
| Q4 25 | — | 0.56× | ||
| Q3 25 | 0.50× | 1.42× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 1.37× | ||
| Q4 24 | — | -1.58× | ||
| Q3 24 | — | 2.16× | ||
| Q2 24 | — | 1.94× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
